CASI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CASI Pharmaceuticals Inc is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is facing significant challenges, including delisting from Nasdaq, a massive price drop, poor financial performance, and no positive trading signals. The lack of positive catalysts and the transition to OTC markets further increase the risk, making it unsuitable for the given investor profile.
The technical indicators are overwhelmingly bearish. The MACD is negative and expanding downward, RSI is at 10.436 indicating extreme oversold conditions, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading far below key support levels, with S2 at 0.166, indicating a lack of price stability.
NULL identified. The company claims minimal operational impact from the delisting, but this is not a strong positive catalyst.
CASI Pharmaceuticals has been delisted from Nasdaq due to failure to meet listing requirements, leading to a 74.06% price drop. The transition to OTC markets raises concerns about liquidity and accessibility. Financial performance is weak, with a 60.54% YoY revenue drop and negative net income.
In Q3 2025, revenue dropped 60.54% YoY to $3,075,000. Net income improved slightly but remains negative at -$10,883,000. EPS improved to -0.68, up 23.64% YoY, but gross margin dropped significantly to 22.96%, down 55.77% YoY. Overall, financials indicate poor performance and declining operational efficiency.
No recent analyst ratings or price target changes are available for CASI Pharmaceuticals.
